Melissa A Wilson Kelly Guld Steven Galetta Ryan D Walsh Julia Kharlip Madhura Tamhankar Suzanne McGettigan Lynn M Schuchter Leslie A Fecher
10.1186/s40425-016-0170-9
J Immunother Cancer
2016 Oct 18;4:66.
checkpoint inhibitors immune ipilimumab melanoma optic neuritis side effects
CC BY
https://pubmed.ncbi.nlm.nih.gov/27777775/
Antineoplastic Agents, Immunological / adverse effects Ipilimumab / adverse effects Melanoma / complications Vision Disorders / diagnosis Vision Disorders / etiology
Antineoplastic Agents, Immunological / adverse effects Ipilimumab / adverse effects Melanoma / complications Vision Disorders / diagnosis Vision Disorders / etiology Case Reports Research Support, N.I.H., Extramural Acute Disease Antineoplastic Agents, Immunological / therapeutic use Biomarkers Brain / pathology CTLA-4 Antigen / antagonists & inhibitors Fluorescein Angiography Humans Ipilimumab / therapeutic use Magnetic Resonance Imaging Male Melanoma / drug therapy Melanoma / pathology Middle Aged Molecular Targeted Therapy / adverse effects Neoplasm Metastasis Optic Nerve / pathology Vision Tests Antineoplastic Agents, Immunological Biomarkers CTLA-4 Antigen Ipilimumab
PMC5067900
27777775
Acute visual loss after ipilimumab treatment for metastatic melanoma
2016